BRAF inhibitor unveils its potential against advanced melanoma.
Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 that validate oncogene-targeted melanoma therapy.
The Wistar Institute, Philadelphia, PA 19104, USA.
Adina
A
Vultur
Jessie
J
Villanueva
Meenhard
M
Herlyn